Modern strategies of regenerative therapy and safety of allogenous human umbilical cord blood stem cellsadministration for neurodegenerative diseases
A B Smolyaninov , O G Hurtsilava , V V Tyrenko , A V Novitsky , D A Ivolgin
Genes & Cells ›› 2011, Vol. 6 ›› Issue (4) : 14 -20.
Modern strategies of regenerative therapy and safety of allogenous human umbilical cord blood stem cellsadministration for neurodegenerative diseases
Biotechnological market in harvesting and application ofumbilical cord blood stem cells, is permanently developing inthe world. Efficiency of regenerative therapy, based on useof cord blood stem cells depends on the number and diversityof HLA-typed cord blood units. Human umbilical cord blood isa genuine source of the stem cells rich biological material,important for human. 114 patients with neurodegenerativediseases were transplanted with allogenic umbilical cordblood. Cord blood stem cells were used without selection byHLA antigens, but only by ABO blood group and Rh factor. Thepossibility of using of allogenic umbilical cord blood stem cellsin regenerative therapy, and the lack of immunosupressionwill overcome significant obstacles existing in cell therapy todate. In practical terms, its becoming clear that extensiveapplication of allogenic umbilical cord blood stem cellsregenerative therapy will seriously changes approaches to thedevelopment and delivery of umbilical blood stem cells-baseddrugs existing nowadays and approved by many generationsof doctors.
| [1] |
Hutton J.F., Gargett T., Sadlon T.J. et al. Development of CD4+CD25+FoxP3+ regulatory T-cells from cord blood hematopoietic progenitor cells. Leukoc. Biol. 2009; 85: 445-1. |
| [2] |
Haller M.J., Wasserfall C.H., McGrail K.M. et al. Autologous umbilical cord blood transfusion in very young children with type I diabetes. Diabetes Care. 2009; 32: 2041-. |
| [3] |
Moon Y.J., Yoon H.H., Lee M.W. et al. Multipotent progenitor cells derived from human umbilical cord blood can differentiate into hepatocyte-like cells in a liver injury rat model. Transplant. Proc. 2009; 41: 4357-0. |
| [4] |
Riordan N.H., Ichim T.E., Min W.P. et al. Nonexpanded adipose stromal vascular fraction cell therapy for multiple sclerosis. Transl. Med. 2009; 7: 29. |
| [5] |
Javed M.J., Mead L.E., Prater D. et al. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatr. Res. 2008; 64: 68-3. |
| [6] |
Gratwohl A., Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr. Opin. Hematol. 2009; 16: 420-. |
| [7] |
Harris D.T. Non-haematological uses of cord blood stem cells. Br. J. Haematol. 2009; 147: 177-4. |
| [8] |
Liu W.S., Chen C.T., Foo N.H. et al. Human umbilical cord blood cells protect against hypothalamic apoptosis and systemic inflammation response during heatstroke in rats. Pediatr. Neonatol. 2009; 50: 208-6. |
| [9] |
Xiao J., Nan Z., Motooka Y. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev. 2005;14: 722-3. |
| [10] |
Riordan N.H., Chan K., Marleau A.M. Cord blood in regenerative medicine: do we need immune suppression? Transl. Med. 2007; 5: 8. |
| [11] |
Ghen M.J., Roshan R., Roshan R.O. et al. Potential clinical applications using stem cells derived from human umbilical cord blood. Reprod. Biomed. Online. 2006; 13: 562-2. |
| [12] |
Xing Y.L., Shen L.H., Li H.W. et al. Optimal time for human umbilical cord blood cell transplantation in rats with myocardial infarction. Chin. Med. J. (Engl). 2009; 122: 2833-39. |
| [13] |
Ichim T.E., Solano F., Brenes R. et al. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod. Biomed. Online. 2008; 16: 898-905. |
| [14] |
Yang W.Z., Zhang Y., Wu F. et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions (Shenzhen Beike Cell Engineering Research Institute, Shenzhen, China). Transl. Med. 2010; 8(75): 1-6. |
| [15] |
Hwang W.S., Chen S.H., Lin C.H. et al. Human umbilical cord blood-derived CD34+ cells can be used as a prophylactic agent for experimental heatstroke. J. Pharmacol. Sci. 2008; 106: 46-55. |
| [16] |
Garbuzova-Davis S., Willing A.E., Zigova T. et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. Hematother. Stem Cell Res. 2003; 12: 255-70. |
| [17] |
Bachstetter A.D., Pabon M.M., Cole M.J. et al. Perepheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci. 2008; 9: 22. |
Eco-Vector
/
| 〈 |
|
〉 |